US lawsuit filed against Rigel on lead RA candidate
This article was originally published in Scrip
Executive Summary
A US class action lawsuit has been filed against Rigel Pharmaceuticals and certain of its officers and directors, alleging that the defendants violated US securities laws by making market statements between December 13th, 2007, and October 27th, 2008, which contained misrepresentations about the company's lead investigational candidate, the novel syk kinase inhibitor for rheumatoid arthritis, R788. The product is in Phase II trials.